Cargando…

Peptide-based delivery of therapeutics in cancer treatment

Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery systems have shown the ability to alleviate these issues and can sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Samec, Timothy, Boulos, Jessica, Gilmore, Serena, Hazelton, Anthony, Alexander-Bryant, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010702/
https://www.ncbi.nlm.nih.gov/pubmed/35434595
http://dx.doi.org/10.1016/j.mtbio.2022.100248
_version_ 1784687538511806464
author Samec, Timothy
Boulos, Jessica
Gilmore, Serena
Hazelton, Anthony
Alexander-Bryant, Angela
author_facet Samec, Timothy
Boulos, Jessica
Gilmore, Serena
Hazelton, Anthony
Alexander-Bryant, Angela
author_sort Samec, Timothy
collection PubMed
description Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery systems have shown the ability to alleviate these issues and can significantly enhance therapeutic loading, delivery, and cancer targetability. Peptide systems can be tailor-made for specific cancer applications. This review describes three peptide classes, targeting, cell penetrating, and fusogenic peptides, as stand-alone nanoparticle systems, conjugations to nanoparticle systems, or as the therapeutic modality. Peptide nanoparticle design, characteristics, and applications are discussed as well as peptide applications in the clinical space.
format Online
Article
Text
id pubmed-9010702
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90107022022-04-16 Peptide-based delivery of therapeutics in cancer treatment Samec, Timothy Boulos, Jessica Gilmore, Serena Hazelton, Anthony Alexander-Bryant, Angela Mater Today Bio Review Article Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery systems have shown the ability to alleviate these issues and can significantly enhance therapeutic loading, delivery, and cancer targetability. Peptide systems can be tailor-made for specific cancer applications. This review describes three peptide classes, targeting, cell penetrating, and fusogenic peptides, as stand-alone nanoparticle systems, conjugations to nanoparticle systems, or as the therapeutic modality. Peptide nanoparticle design, characteristics, and applications are discussed as well as peptide applications in the clinical space. Elsevier 2022-03-30 /pmc/articles/PMC9010702/ /pubmed/35434595 http://dx.doi.org/10.1016/j.mtbio.2022.100248 Text en © 2022 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Samec, Timothy
Boulos, Jessica
Gilmore, Serena
Hazelton, Anthony
Alexander-Bryant, Angela
Peptide-based delivery of therapeutics in cancer treatment
title Peptide-based delivery of therapeutics in cancer treatment
title_full Peptide-based delivery of therapeutics in cancer treatment
title_fullStr Peptide-based delivery of therapeutics in cancer treatment
title_full_unstemmed Peptide-based delivery of therapeutics in cancer treatment
title_short Peptide-based delivery of therapeutics in cancer treatment
title_sort peptide-based delivery of therapeutics in cancer treatment
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010702/
https://www.ncbi.nlm.nih.gov/pubmed/35434595
http://dx.doi.org/10.1016/j.mtbio.2022.100248
work_keys_str_mv AT samectimothy peptidebaseddeliveryoftherapeuticsincancertreatment
AT boulosjessica peptidebaseddeliveryoftherapeuticsincancertreatment
AT gilmoreserena peptidebaseddeliveryoftherapeuticsincancertreatment
AT hazeltonanthony peptidebaseddeliveryoftherapeuticsincancertreatment
AT alexanderbryantangela peptidebaseddeliveryoftherapeuticsincancertreatment